User menu

A phase I study comparing the safety, pharmacokinetics, and pharmacodynamics of infliximab administered by the subcutaneous, intravenous followed by subcutaneous, or intramuscular routes of administration in rheumatoid arthritis patients.

Bibliographic reference Westhovens, Rene ; Durez, Patrick ; Hollssiau, FA ; Joly, Jeroen ; Daniel, EE ; et. al. A phase I study comparing the safety, pharmacokinetics, and pharmacodynamics of infliximab administered by the subcutaneous, intravenous followed by subcutaneous, or intramuscular routes of administration in rheumatoid arthritis patients..68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (San Antonio (Tx), Oct 16-21, 2004). In: Arthritis & Rheumatism, Vol. 50, no. 9, p. S179-S179 (2004)
Permanent URL http://hdl.handle.net/2078.1/61050